Short summary: Finerenone, sold as Kerendia, is a prescription medicine used in selected adults with chronic kidney disease associated with type 2 diabetes. It can reduce certain kidney and heart risks, but it requires potassium and kidney-function monitoring.
Key takeaways
- Finerenone is a nonsteroidal mineralocorticoid receptor antagonist, often shortened to MRA.
- The FDA label is for adults with chronic kidney disease associated with type 2 diabetes.
- High potassium is a key safety concern, so blood tests are part of safe prescribing.
What finerenone is
Finerenone blocks mineralocorticoid receptors. Overactivation of these receptors can contribute to inflammation and scarring in the kidneys and heart. By blocking that pathway, finerenone may help reduce kidney and cardiovascular complications in selected people.
It is not the same as an SGLT2 inhibitor, GLP-1 receptor agonist, ACE inhibitor, or ARB. Many people with diabetes-related kidney disease use more than one evidence-based therapy, but the exact combination depends on kidney function, potassium, blood pressure, albumin in the urine, other medications, and side-effect risk.
Who it is for
The FDA label indicates Kerendia to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal heart attack, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.
That wording is specific. It does not mean finerenone is for every person with diabetes, every person with reduced kidney function, or people with type 1 diabetes unless a clinician is using evidence and labeling appropriately for an individual situation.
The approval evidence base includes the FIDELIO-DKD and FIGARO-DKD trials, which studied adults with chronic kidney disease associated with type 2 diabetes. FIDELIO-DKD focused more on kidney outcomes in people with more advanced CKD, while FIGARO-DKD focused on cardiovascular outcomes in people with a broader CKD range.
Why potassium monitoring matters
Finerenone can raise potassium. High potassium can be dangerous because it may affect heart rhythm. The label advises measuring serum potassium and estimated glomerular filtration rate before starting treatment and using potassium thresholds to decide whether to start, adjust, pause, or continue therapy.
Risk can be higher when kidney function is reduced or when other medicines also raise potassium. That is why this medicine should be managed through a prescribing clinician, not started or stopped casually.
How it fits with diabetes kidney care
Diabetes kidney care usually starts with regular screening for urine albumin and eGFR, blood pressure control, blood sugar management, and medication choices with proven kidney and heart benefit. ADA kidney standards include monitoring albuminuria, eGFR, and potassium in people receiving medicines that can affect kidney function or potassium.
For more background, read our guides to diabetes complications, kidney disease in diabetes, and SGLT2 inhibitors for kidney protection.
Practical takeaway
If you have type 2 diabetes and kidney disease, ask whether your urine albumin, eGFR, potassium, blood pressure, and medication list have been reviewed together. Finerenone may be useful for some people, but safe use depends on the right diagnosis, lab monitoring, and medication plan.
Sources
- FDA: Kerendia prescribing information
- DailyMed: Kerendia label
- American Diabetes Association: Chronic Kidney Disease and Risk Management Standards 2026
- New England Journal of Medicine: FIDELIO-DKD trial
- New England Journal of Medicine: FIGARO-DKD trial
Editorial review note: reviewed for medical accuracy, source consistency, patient-safety framing, medication-label wording, and plain-language readability before publication.